Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review

Clin Neuroradiol. 2022 Sep;32(3):625-641. doi: 10.1007/s00062-022-01144-3. Epub 2022 Mar 8.

Abstract

The recently developed effective treatment of primary progressive multiple sclerosis (PPMS) requires the accurate diagnosis of patients with this type of disease. Currently, the diagnosis of PPMS is based on the 2017 McDonald criteria, although the contribution of magnetic resonance imaging (MRI) to this process is fundamental. PPMS, one of the clinical types of MS, represents 10%-15% of all MS patients. Compared to relapsing-remitting MS (RRMS), PPMS differs in terms of pathology, clinical presentation and MRI features. Regarding conventional MRI, focal lesions on T2-weighted images and acute inflammatory lesions with contrast enhancement are less common in PPMS than in RRMS. On the other hand, MRI features of chronic inflammation, such as slowly evolving/expanding lesions (SELs) and leptomeningeal enhancement (LME), and brain and spinal cord atrophy are more common MRI characteristics in PPMS than RRMS. Nonconventional MRI also shows differences in subtle white and grey matter damage between PPMS and other clinical types of disease. In this review, we present separate diagnostic criteria, conventional and nonconventional MRI specificity for PPMS, which may support and simplify the diagnosis of this type of MS in daily clinical practice.

Keywords: Diagnosis of multiple sclerosis; Differential diagnosis.

Publication types

  • Review

MeSH terms

  • Brain
  • Gray Matter
  • Humans
  • Magnetic Resonance Imaging
  • Multiple Sclerosis*
  • Multiple Sclerosis, Chronic Progressive*
  • Recurrence